Trials / Completed
CompletedNCT04775069
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 Vaccines
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 232 (actual)
- Sponsor
- Humanity & Health Medical Group Limited · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Currently the Pfizer-Biontech (mRNA), Sinovac (inactivated virus) and Astrazeneca-Oxford (adenovirus-vector) COVID-19 vaccines are available for vaccination in HK. The American Association of Liver Disease has recently published consensus statements for COVID-19 vaccination in subjects with chronic liver disease (CLD). Patients with CLD have dysregulated innate and adaptive immune response that may be associated with vaccine hypo-responsiveness and there are no data as to whether these patients may respond differently to the various vaccines. The Humanity and Health Medical Center (HHMC) is an active participant of the HK government COVID-19 vaccination programs and patients with CLD follow-up at HHMC will have access to the three different vaccines. The aim of this prospective study is to compare the antibody response of CLD subjects to the Pfizer-Biontech (mRNA), Sinovac (inactivated virus) and Astrazeneca-Oxford (adenovirus-vector) COVID-19 vaccines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BNT162b2 | Intramuscular injection |
| BIOLOGICAL | CoronaVac | Intramuscular injection |
| BIOLOGICAL | AZD1222 | Intramuscular injection |
Timeline
- Start date
- 2021-05-21
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
- First posted
- 2021-03-01
- Last updated
- 2023-10-04
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT04775069. Inclusion in this directory is not an endorsement.